RxDoctor Payments Data

Christine Hoffpauir, NP

Family · Deridder, LANPI 1063087112

Payments from drug & device makers

$309in general payments, 2019–2025

Across 17 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$54
  • Novo Nordisk$49
  • AbbVie$39
  • Lilly USA, LLC$34
  • Hologic Sales And Service, LLC$33
  • Mayne Pharma Commercial LLC$28
  • plus $72 from 4 others

What the payments were for

  • Food & beverage$309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$309 in reported general payments places this provider in the 35th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$12,971
Medicare patients
51
Services billed
427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast12$67,882
JardianceEmpagliflozin20$16,909
OzempicSemaglutide16$14,969
MyrbetriqMirabegron12$5,673
VascepaIcosapent Ethyl15$5,252
Tizanidine Hcl23$2,051
Gabapentin71$1,371
Albuterol Sulfate HfaAlbuterol Sulfate54$1,333
Oxybutynin Chloride ErOxybutynin Chloride21$966
Levetiracetam12$927
Potassium Chloride41$689
Atorvastatin Calcium69$671
Ezetimibe39$554
Levothyroxine Sodium63$515
Losartan Potassium37$440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$54$67,88212 claims
Novo NordiskOzempic$49$14,96916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 3,610 family providers in Louisiana.

Other family in Deridder

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →